Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM ...
BridgeBio reports pre-specified subgroup analysis of ATTRibute-CM trial
Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Healio1d
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
Managed Healthcare Executive13d
FDA Approves Amvuttra for ATTR-CM in Extended Label
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
Morningstar3d
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis ...
pharmaphorum13d
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
TCTMD13d
Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...